Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy

References

• Manieri E, Herrera-Melle L, Mora A, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216(5):1108–1119. doi:10.1084/jem.2018128830944152
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–761. doi:10.1053/j.gastro.2016.11.04828043904
   PubMed Web of Science ®Google Scholar
• Gravitz L. Liver cancer. Nature. 2014;516(7529):S1. doi:10.1038/516S1a25470192
   PubMed Web of Science ®Google Scholar
• Yin T, Wang L, Yin L, et al. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials. 2015;61:10–25. doi:10.1016/j.biomaterials.2015.05.02225996409
   PubMed Web of Science ®Google Scholar
• Ma B, Zhuang W, Wang Y, et al. pH-sensitive doxorubicin-conjugated prodrug micelles with charge-conversion for cancer therapy. Acta Biomater. 2018;70:186–196. doi:10.1016/j.actbio.2018.02.00829452272
   PubMed Web of Science ®Google Scholar
• Bae KH, Tan S, Yamashita A, et al. Hyaluronic acid-green tea catechin micellar nanocomplexes: fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity. Biomaterials. 2017;148:41–53. doi:10.1016/j.biomaterials.2017.09.02728961534
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang F, Liu Y, et al. Glutathione detonated and pH responsive nano-clusters of Au nanorods with a high dose of DOX for treatment of multidrug resistant cancer. Acta Biomater. 2018;75:334–345. doi:10.1016/j.actbio.2018.06.01229885528
   PubMed Web of Science ®Google Scholar
• Kesharwani SS, Kaur S, Tummala H. Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opin Drug Deliv. 2018;15(11):1127–1142. doi:10.1080/17425247.2018.153726130324813
   PubMed Web of Science ®Google Scholar
• Kesharwani SS, Kaur S, Tummala H. Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors. Colloids Surf B Biointerfaces. 2019;173:581–590. doi:10.1016/j.colsurfb.2018.10.02230352379
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhang H, Li W, et al. Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle. Biomaterials. 2018;161:144–153. doi:10.1016/j.biomaterials.2018.01.04329421551
   PubMedGoogle Scholar
• Chen Z, He N, Chen M, et al. Tunable conjugation densities of camptothecin on hyaluronic acid for tumor targeting and reduction-triggered release. Acta Biomater. 2016;43:195–207. doi:10.1016/j.actbio.2016.07.02027424081
   PubMed Web of Science ®Google Scholar
• Yin S, Huai J, Chen X, et al. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015;26:274–285. doi:10.1016/j.actbio.2015.08.02926300335
   PubMed Web of Science ®Google Scholar
• Liu Y, Qiao L, Zhang S, et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 2018;66:310–324. doi:10.1016/j.actbio.2017.11.01029129789
   PubMed Web of Science ®Google Scholar
• Choi KY, Han HS, Lee ES, et al. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: beyond CD44-mediated drug delivery. Adv Mater;2019;e1803549. doi:10.1002/adma.20180354930773699
   PubMedGoogle Scholar
• Qiu L, Qiao M, Chen Q, et al. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials. 2014;35(37):9877–9887. doi:10.1016/j.biomaterials.2014.08.00825201738
   PubMed Web of Science ®Google Scholar
• Dosio F, Arpicco S, Stella B. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev. 2016;97:204–236. doi:10.1016/j.addr.2015.11.01126592477
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Mirza S. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res. 2014;123:35–65.25081525
   PubMed Web of Science ®Google Scholar
• Benitez A, Yates TJ, Lopez LE, et al. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011;71(12):4085–4095. doi:10.1158/0008-5472.CAN-10-461021555367
   PubMedGoogle Scholar
• Jordan AR, Lokeshwar SD, Lopez LE, et al. Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget. 2017;8(15):24262–24274. doi:10.18632/oncotarget.v8i1527419371
   PubMedGoogle Scholar
• Isoyama T, Thwaites D, Selzer MG, et al. Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases. Glycobiology. 2006;16(1):11–21. doi:10.1093/glycob/cwj03616166602
   PubMedGoogle Scholar
• Lim DK, Wylie RG, Langer R. Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165). Biomaterials. 2016;77:130–138. doi:10.1016/j.biomaterials.2015.10.07426588795
   PubMedGoogle Scholar
• Wu JL, Liu CG, Wang XL. Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers. J Mater Sci Mater Med. 2012;23(8):1921–1929. doi:10.1007/s10856-012-4665-822580754
   PubMedGoogle Scholar
• Sun Y, Dai C, Yin M, et al. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes. Int J Nanomedicine. 2018;13:1621–1632.29588589
   PubMed Web of Science ®Google Scholar
• Mezghrani O, Tang Y, Ke X, et al. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Int J Pharm. 2015;478(2):553–568. doi:10.1016/j.ijpharm.2014.10.04125455765
   PubMedGoogle Scholar
• Lv Y, Xu C, Zhao X, et al. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano. 2018;12(2):1519–1536. doi:10.1021/acsnano.7b0805129350904
   PubMed Web of Science ®Google Scholar
• Ge Z. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chem Soc Rev. 2013;42(17):7289–7325. doi:10.1039/c3cs60048c23549663
   PubMed Web of Science ®Google Scholar
• Venditto VJ. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65(1):80–88. doi:10.1016/j.addr.2012.09.03823036224
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li P, Pan H, et al. Retinal-conjugated pH-sensitive micelles induce tumor senescence for boosting breast cancer chemotherapy. Biomaterials. 2016;83:219–232. doi:10.1016/j.biomaterials.2016.01.02326774567
   PubMed Web of Science ®Google Scholar
• Zhu D, Fan F, Huang C, et al. Bubble-generating polymersomes loaded with both indocyanine green and doxorubicin for effective chemotherapy combined with photothermal therapy. Acta Biomater. 2018;75:386–397. doi:10.1016/j.actbio.2018.05.03329793073
   PubMedGoogle Scholar
• Zhang P, Li J, Ghazwani M, et al. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials. 2015;67:104–114. doi:10.1016/j.biomaterials.2015.07.02726210177
   PubMed Web of Science ®Google Scholar
• Gupta B, Poudel BK, Ruttala HB, et al. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin. Acta Biomater. 2018;80:364–377. doi:10.1016/j.actbio.2018.09.00630201431
   PubMed Web of Science ®Google Scholar
• Wu JL, Tian GX, Yu WJ, et al. pH-responsive hyaluronic acid-based mixed micelles for the hepatoma-targeting delivery of doxorubicin. Int J Mol Sci. 2016;17(4):364. doi:10.3390/ijms1704036427043540
   PubMed Web of Science ®Google Scholar
• Fu C, Li H, Li N, et al. Conjugating an anticancer drug onto thiolated hyaluronic acid by acid liable hydrazone linkage for its gelation and dual stimuli-response release. Carbohydr Polym. 2015;128:163–170. doi:10.1016/j.carbpol.2015.04.02426005152
   PubMed Web of Science ®Google Scholar
• Tian G, Pan R, Zhang B, et al. Liver-Targeted combination therapy basing on glycyrrhizic acid-modified DSPE-PEG-PEI nanoparticles for co-delivery of doxorubicin and Bcl-2 siRNA. Front Pharmacol. 2019;10:4. doi:10.3389/fphar.2019.0000430723405
   PubMed Web of Science ®Google Scholar
• Chen WL, Yang SD, Li F, et al. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo. Acta Biomater. 2018;81:219–230. doi:10.1016/j.actbio.2018.09.04030267887
   PubMed Web of Science ®Google Scholar
• Bao X, Wang W, Wang C, et al. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. Biomaterials. 2014;35(29):8450–8466. doi:10.1016/j.biomaterials.2014.06.02524997481
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Shi Z, et al. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater. 2017;58:349–364. doi:10.1016/j.actbio.2017.04.02928455219
   PubMed Web of Science ®Google Scholar
• Wang J, Wang M, Zheng M, et al. Folate mediated self-assembled phytosterol-alginate nanoparticles for targeted intracellular anticancer drug delivery. Colloids Surf B Biointerfaces. 2015;129:63–70. doi:10.1016/j.colsurfb.2015.03.02825829128
   PubMed Web of Science ®Google Scholar
• Qi WW, Yu HY, Guo H, et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharm. 2015;12(3):675–683. doi:10.1021/mp500394v25584860
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang M, Ji J, et al. Glycyrrhetinic acid-mediated polymeric drug delivery targeting the acidic microenvironment of hepatocellular carcinoma. Pharm Res. 2015;32(10):3376–3390. doi:10.1007/s11095-015-1714-226148773
   PubMed Web of Science ®Google Scholar
• Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31(17):4748–4756. doi:10.1016/j.biomaterials.2010.02.04220303163
   PubMed Web of Science ®Google Scholar
• Dai Y, Xu C, Sun X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017;46(12):3830–3852. doi:10.1039/C6CS00592F28516983
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang T, Yang S, et al. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J Control Release. 2016;238:10–21. doi:10.1016/j.jconrel.2016.07.02227432750
   PubMed Web of Science ®Google Scholar